-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Maintains Overweight on Pharvaris, Raises Price Target to $62

Benzinga·09/09/2026 17:31:28
语音播报
Morgan Stanley analyst Maxwell Skor maintains Pharvaris (NASDAQ:PHVS) with a Overweight and raises the price target from $46 to $62.